Predict your next investment

Venture Capital
vidaventures.com

See what CB Insights has to offer

Investments

38

Portfolio Exits

11

Funds

6

About Vida Ventures

Vida Ventures is a next-generation, life sciences venture capital firm that invests in asset efficient, technology, or technology-enabled business models.

Vida Ventures Headquarter Location

40 Broad Street Suite 201

Boston, Massachusetts, 2109,

United States

857-254-9500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Vida Ventures News

Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs

Oct 27, 2021

Series C Financing Led by Surveyor Capital (a Citadel company) and Vida Ventures Differentiated mechanisms target RAS active conformation across all mutant forms, with potential to circumvent resistance mechanisms experienced with first generation KRAS inhibitors SAN FRANCISCO, October 26, 2021-- Quanta Therapeutics, Inc., a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, today announced that it has successfully closed a $60 Million Series C financing round led by Surveyor Capital (a Citadel company) and Vida Ventures. New investors Longitude Capital and BVF Partners joined existing investors Sofinnova Investments, Logos Capital, AbbVie Ventures, and Vida Ventures (who also led Quanta’s Series B financing round). "We are thrilled to have this unique opportunity to partner with a high-quality investor base as we merge novel protein structural insights, leading technology in detection of conformational drug activity, and sophisticated medicinal chemistry expertise to develop differentiated therapeutics for the benefit of patients suffering from RAS-driven cancers,” said Perry Nisen, MD, PhD, Quanta Chief Executive Officer. “This influx of capital will allow us to continue advancing rational strategies to expand the breadth and duration of benefit for patients with poor existing options and we look forward to the next chapter of growth for Quanta.” The company was founded in 2018 by Sofinnova Investments, alongside co-founder and scientific luminary Frank McCormick, PhD, FRS, with the goal to build a platform that allosterically targets previously undruggable driver oncoprotein signaling complexes. Quanta had previously raised $32 Million while in stealth since its inception in 2018. “As all oncogenic forms of RAS undergo conformational change to drive functional effector protein-protein interactions, there was a clear Achilles’ heel in targeting these shared interactions in the active conformation with our platform,” said Cameron Pitt, PhD, Quanta Chief Business Officer & co-founder. “Founded on compelling science, Quanta’s novel approach has the potential to transform the treatment paradigm for patients with RAS mutations, activated in nearly a third of all human cancers,” said Arjun Goyal, MD, Co-Founder and Managing Director, Vida Ventures. “We are proud to support this experienced and accomplished team of scientists and biotech executives as they advance their bold vision to address this important unmet need for patients globally.” The Company will use proceeds from this financing round to advance programs targeting RAF1 and KRAS through clinical candidate selection, and IND filing, to reach initial proof-of-concept. Leveraging a differentiated mechanism targeting the active conformation of RAS, the Quanta team believes their unique approach, with applicability across mutant RAS forms, will circumvent resistance mechanisms experienced with first generation inhibitors of KRAS G12C. About Quanta Quanta Therapeutics, Inc. is a privately-held biopharmaceutical company focused on first-in-class direct approaches targeting the protein interactions key to oncogenic RAS activity. RAS is the most prevalent and elusive target in oncology. Quanta’s success thus far has driven by their uniquely developed platform, applying Second Harmonic Generation (SHG) optical technology to identify modulators of membrane-protein-complex conformation in real-time drug screening and yielding unparalleled sensitivity to detect change in functional states. The Quanta team has extensive drug development expertise and substantial research experience in the RAS space. Application of unique protein conformation detection technology and medicinal chemistry expertise is anticipated to yield novel small molecules as first-in-class precision medicines designed to address the resistance paradigms of targeted therapy in oncology. Learn more at https://www.quantatx.com/. Contact:

Vida Ventures Investments

38 Investments

Vida Ventures has made 38 investments. Their latest investment was in Recode Therapeutics as part of their Series B on October 10, 2021.

CBI Logo

Vida Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/21/2021

Series B

Recode Therapeutics

$80M

No

4

8/18/2021

Series B

Vigil Neuroscience

$90M

Yes

9

4/15/2021

Series A

Tectonic Therapeutic

$80M

Yes

6

4/6/2021

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

3/18/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/21/2021

8/18/2021

4/15/2021

4/6/2021

3/18/2021

Round

Series B

Series B

Series A

Series A - II

Series A

Company

Recode Therapeutics

Vigil Neuroscience

Tectonic Therapeutic

Subscribe to see more

Subscribe to see more

Amount

$80M

$90M

$80M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

9

6

10

10

Vida Ventures Portfolio Exits

11 Portfolio Exits

Vida Ventures has 11 portfolio exits. Their latest portfolio exit was Centessa Pharmaceuticals on May 28, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/28/2021

IPO

$991

1

12/3/2020

IPO

$991

1

10/26/2020

Acquired

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

5/28/2021

12/3/2020

10/26/2020

00/00/0000

00/00/0000

Exit

IPO

IPO

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Vida Ventures Fund History

6 Fund Histories

Vida Ventures has 6 funds, including Vida Ventures III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/24/2021

Vida Ventures III

$825M

3

8/1/2019

Vida Ventures II

Subscribe to see more

$99M

10

7/15/2019

Vida Ventures II-A

Subscribe to see more

$99M

10

4/22/2019

VV Atreus Special Fund

Subscribe to see more

$99M

10

6/1/2018

VVAG Special Fund

Subscribe to see more

$99M

10

Closing Date

6/24/2021

8/1/2019

7/15/2019

4/22/2019

6/1/2018

Fund

Vida Ventures III

Vida Ventures II

Vida Ventures II-A

VV Atreus Special Fund

VVAG Special Fund

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$825M

$99M

$99M

$99M

$99M

Sources

3

10

10

10

10

Vida Ventures Team

3 Team Members

Vida Ventures has 3 team members, including current Senior Managing Director, Helen S. Kim.

Name

Work History

Title

Status

Fred E. Cohen

Founder

Current

Stefan Vitorovic

Founder

Current

Helen S. Kim

The Column Group, Kosan Biosciences, Gordon and Betty Moore Foundation, Affymax, Onyx Pharmaceuticals, PDL BioPharma, and Chiron

Senior Managing Director

Current

Name

Fred E. Cohen

Stefan Vitorovic

Helen S. Kim

Work History

The Column Group, Kosan Biosciences, Gordon and Betty Moore Foundation, Affymax, Onyx Pharmaceuticals, PDL BioPharma, and Chiron

Title

Founder

Founder

Senior Managing Director

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.